BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 20205253)

  • 1. Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
    Steinherz PG; Shukla N; Kobos R; Steinherz L
    Pediatr Blood Cancer; 2010 May; 54(5):687-93. PubMed ID: 20205253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
    Shukla N; Kobos R; Renaud T; Steinherz LJ; Steinherz PG
    Pediatr Blood Cancer; 2014 Mar; 61(3):431-5. PubMed ID: 24115731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
    Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ
    Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia.
    Hijiya N; Gaynon P; Barry E; Silverman L; Thomson B; Chu R; Cooper T; Kadota R; Rytting M; Steinherz P; Shen V; Jeha S; Abichandani R; Carroll WL
    Leukemia; 2009 Dec; 23(12):2259-64. PubMed ID: 19741725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
    Locatelli F; Testi AM; Bernardo ME; Rizzari C; Bertaina A; Merli P; Pession A; Giraldi E; Parasole R; Barberi W; Zecca M
    Br J Haematol; 2009 Nov; 147(3):371-8. PubMed ID: 19747360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee).
    Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P
    Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clofarabine in combination with a standard remission induction regimen (cytosine arabinoside and idarubicin) in patients with previously untreated intermediate and bad-risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): phase I results of an ongoing phase I/II study of the leukemia groups of EORTC and GIMEMA (EORTC GIMEMA 06061/AML-14A trial).
    Willemze R; Suciu S; Muus P; Halkes CJ; Meloni G; Meert L; Karrasch M; Rapion J; Vignetti M; Amadori S; de Witte T; Marie JP
    Ann Hematol; 2014 Jun; 93(6):965-75. PubMed ID: 24682421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
    Scappini B; Gianfaldoni G; Caracciolo F; Mannelli F; Biagiotti C; Romani C; Pogliani EM; Simonetti F; Borin L; Fanci R; Cutini I; Longo G; Susini MC; Angelucci E; Bosi A
    Am J Hematol; 2012 Dec; 87(12):1047-51. PubMed ID: 23151979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.
    Cooper BW; Veal GJ; Radivoyevitch T; Tilby MJ; Meyerson HJ; Lazarus HM; Koc ON; Creger RJ; Pearson G; Nowell GM; Gosky D; Ingalls ST; Hoppel CL; Gerson SL
    Clin Cancer Res; 2004 Oct; 10(20):6830-9. PubMed ID: 15501959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
    Jeha S; Gaynon PS; Razzouk BI; Franklin J; Kadota R; Shen V; Luchtman-Jones L; Rytting M; Bomgaars LR; Rheingold S; Ritchey K; Albano E; Arceci RJ; Goldman S; Griffin T; Altman A; Gordon B; Steinherz L; Weitman S; Steinherz P
    J Clin Oncol; 2006 Apr; 24(12):1917-23. PubMed ID: 16622268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
    Kolb EA; Steinherz PG
    Leukemia; 2003 Oct; 17(10):1967-72. PubMed ID: 14513046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
    Farag SS; Wood LL; Schwartz JE; Srivastava S; Nelson RP; Robertson MJ; Abonour R; Secrest A; Cox E; Baute J; Sullivan C; Kane K; Jones DR
    Leukemia; 2011 Apr; 25(4):599-605. PubMed ID: 21252987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
    Abbi KK; Rybka W; Ehmann WC; Claxton DF
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):41-6. PubMed ID: 25085441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clofarabine/cyclophosphamide for debulking before stem cell transplantation.
    Rabitsch W; Böhm A; Bojic M; Schellongowski P; Wöhrer S; Sliwa T; Keil F; Worel N; Greinix H; Hauswirth A; Kalhs P; Jaeger U; Valent P; Sperr WR
    Eur J Clin Invest; 2014 Aug; 44(8):775-83. PubMed ID: 24942362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
    Moreno L; Fernandez-Navarro JM; Del Mar Andres M; Bautista F; Tasso M; Verdeguer A
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):e17-21. PubMed ID: 21716139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
    Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
    Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofarabine-based chemotherapy for relapsed/refractory adult acute lymphoblastic leukemia and lymphoblastic lymphoma. The Spanish experience.
    Barba P; Sampol A; Calbacho M; Gonzalez J; Serrano J; Martínez-Sánchez P; Fernández P; García-Boyero R; Bueno J; Ribera JM
    Am J Hematol; 2012 Jun; 87(6):631-4. PubMed ID: 22431002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study in adults of clofarabine combined with high-dose melphalan as reduced-intensity conditioning for allogeneic transplantation.
    Kirschbaum MH; Stein AS; Popplewell L; Delioukina M; Chen R; Nakamura R; Snyder D; Conrad J; Lacey SF; Frankel P; Dagis A; Nademanee A; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):432-40. PubMed ID: 21801703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.